HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Boris Minev Selected Research

HLA Antigens (Human Leukocyte Antigens)

6/2017IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells.
1/2007Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Boris Minev Research Topics

Disease

16Neoplasms (Cancer)
01/2020 - 06/2003
2Prostatic Neoplasms (Prostate Cancer)
12/2019 - 06/2003
2Glioma (Gliomas)
06/2017 - 01/2007
2Sepsis (Septicemia)
05/2014 - 03/2011
1Vaccinia
01/2015
1Renal Cell Carcinoma (Grawitz Tumor)
05/2014
1Melanoma (Melanoma, Malignant)
05/2014
1Neoplasm Metastasis (Metastasis)
01/2013
1Rheumatoid Arthritis
02/2012
1Spinal Cord Injuries (Spinal Cord Injury)
11/2010
1Communicable Diseases (Infectious Diseases)
10/2010
1Graft vs Host Disease (Graft-Versus-Host Disease)
08/2010
1Heart Failure
04/2010
1Multiple Sclerosis
04/2009
1Brain Neoplasms (Brain Tumor)
01/2007
1Body Weight (Weight, Body)
11/2004

Drug/Important Bio-Agent (IBA)

6Peptides (Polypeptides)IBA
01/2020 - 01/2007
3AntigensIBA
11/2017 - 01/2007
3Histocompatibility Antigens Class IIBA
11/2017 - 01/2007
2EpitopesIBA
01/2020 - 01/2007
2SurvivinIBA
01/2020 - 01/2007
2Pharmaceutical PreparationsIBA
12/2019 - 01/2013
2HLA Antigens (Human Leukocyte Antigens)IBA
06/2017 - 01/2007
2Neoplasm Antigens (Tumor Antigens)IBA
06/2017 - 01/2007
2HLA-A2 Antigen (HLA A2 Antigen)IBA
06/2017 - 01/2007
2Proteins (Proteins, Gene)FDA Link
01/2015 - 01/2007
2VaccinesIBA
10/2010 - 01/2007
1Biomarkers (Surrogate Marker)IBA
01/2020
1Biocompatible Materials (Biomaterials)IBA
12/2019
1incomplete Freund's adjuvantIBA
12/2019
1NanovaccinesIBA
12/2019
1Polylactic Acid-Polyglycolic Acid CopolymerIBA
12/2019
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2015
1ErbB Receptors (EGF Receptor)IBA
01/2015
1AntibodiesIBA
01/2015
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2014
1C-Reactive ProteinIBA
05/2014
1Interleukin-2 (IL2)IBA
05/2014
1SuspensionsIBA
07/2012
1Protein Subunit VaccinesIBA
01/2012
1poly(lactide) (polylactic acid)IBA
01/2012
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
03/2011
1Antineoplastic Agents (Antineoplastics)IBA
03/2011
1Subunit VaccinesIBA
10/2010
1tetra-4-amidinophenoxypropane (TAPP)IBA
01/2007
1Messenger RNA (mRNA)IBA
01/2007
1Monophenol Monooxygenase (Tyrosinase)IBA
01/2007
1Cell ExtractsIBA
01/2007
1CyclinsIBA
01/2007
1Interleukin-13 Receptor alpha2 SubunitIBA
01/2007

Therapy/Procedure

12Therapeutics
01/2020 - 01/2007
5Immunotherapy
01/2020 - 06/2003
2Transplantation
08/2010 - 04/2010
1Oncolytic Virotherapy
01/2015
1Drug Therapy (Chemotherapy)
01/2013
1Biological Therapy
02/2012
1Cell- and Tissue-Based Therapy (Cell Therapy)
04/2009
1Intravenous Injections
11/2004